1. Home
  2. VSTM vs VOR Comparison

VSTM vs VOR Comparison

Compare VSTM & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verastem Inc.

VSTM

Verastem Inc.

N/A

Current Price

$7.19

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

N/A

Current Price

$18.27

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VSTM
VOR
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
VSTM
VOR
Price
$7.19
$18.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
10
Target Price
$17.22
★ $39.00
AVG Volume (30 Days)
★ 3.0M
646.7K
Earning Date
11-05-2026
10-30-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 17.49
N/A
EPS
★ N/A
N/A
Revenue
★ $30,914,000.00
N/A
Revenue This Year
$248.46
N/A
Revenue Next Year
$34.25
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 209.14
N/A
52 Week Low
$3.43
$6.50
52 Week High
$10.82
$26.00

Technical Indicators

Market Signals
Indicator
VSTM
VOR
Relative Strength Index (RSI) 31.85 40.76
Support Level $5.26 $17.62
Resistance Level $8.59 $18.28
Average True Range (ATR) 0.57 1.20
MACD -0.31 -0.14
Stochastic Oscillator 0.48 9.97

Price Performance

Historical Comparison
VSTM
VOR

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: